Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Roxarsone is an organoarsenic small molecule formerly used as a feed additive in poultry and swine to promote weight gain, improve feed efficiency, enhance pigmentation, and prevent coccidiosis by acting as a coccidiostat[1][5][7]. Its mechanism of action involves antibacterial activity and inhibition of protozoan parasites such as *Eimeria* species (coccidia)[2][5]. Roxarsone has also been shown to promote angiogenesis and glycolysis in animal models via induction of hypoxia-inducible factor-1α (HIF-1α), which may contribute to tumor growth[6]. The drug was marketed under the brand name 3-Nitro. Use of roxarsone has been discontinued or banned in many countries due to concerns about its metabolism into inorganic arsenic—a known toxin—in edible tissues[3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Roxarsone.